Trial Profile
Kinetic rate proteasome flowing during processing by the proteasome inhibitor (bortezomib Velcade ®) in multiple myeloma [Cinetique du taux de proteasome circulant au cours du traitement par inhibiteur du proteasome (bortezomib, Velcade) au cours du myelome multiple.]
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Aug 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 23 Aug 2011 New trial record